Isis' Balancing Act: Diversify With Cancer, But Avoid High-Stakes Gambles
Executive Summary
Isis tried a delicate balancing act during its May 20 pipeline update: it sought to accentuate its progress in branching out into cancer drug development, while also reassuring investors that its oncology spend is relatively modest and doesn't introduce major risk